Results 71 to 80 of about 6,454 (219)

Rethinking control‐IQ+ technology: Simple strategies for easy optimization

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Control‐IQ+ is an automated insulin delivery (AID) algorithm approved for people with type 1 diabetes aged 2+ years and adults aged 18+ years with type 2 diabetes. While numerous publications support improved glycaemia and quality of life for people with diabetes, this practice paper is intended to encourage uptake for healthcare professionals
Viral N. Shah, Pratik Choudhary, Ilana Halperin, Ivana Rabbone, Dessi P. Zaharieva, Laurel Messer   +5 more
wiley   +1 more source

Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis

BMC Endocrine Disorders
Objective The objective is to assess the effectiveness and safety of tirzepatide, liraglutide, and SGLT2i in individuals diagnosed with type 2 diabetes.
Yunjie Teng, Xue Fan, Rui Yu, Xiaoping Yang   +3 more
doaj   +1 more source

Tirzepatide – a new hope for type 2 diabetes mellitus and obesity management. A literature review. [PDF]

INTRODUCTION AND PURPOSE. While obesity and type 2 diabetes mellitus (T2DM) are defined (according to WHO) as civilization diseases we are still searching for the ideal tool to fight them.
Boczar, Agata, Dryja, Patryk, Jarmołowicz, Jakub, Orzołek, Izabela, Stawicka, Izabela   +4 more
core   +1 more source

Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review. [PDF]

: Background This systematic review is registered with CRD42024507397 protocol number and aims to compare the known data about retatrutide on long-term cardiovascular (CV) protection with tirzepatide, an incretin with recent proven CV benefits.
Bica, Ioana-Cristina, Ciaccio, Marcello, El-Tanani, Mohamed, Gherghiceanu, Florentina, Giglio, Rosaria Vincenza, Janež, Andrej, Patti, Angelo Maria, Potcovaru, Claudia-Gabriela, Rizzo, Manfredi, Salmen, Teodor, Stoian, Anca Pantea, Stoica, Roxana-Adriana   +11 more
core   +1 more source

Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A meta‐analysis

Journal of Diabetes Investigation
Objective To investigate the risk of biliary diseases in patients with type 2 diabetes mellitus (T2DM) or obesity treated with tirzepatide. Methods Literature searches were performed using the PubMed, Web of Science, Cochrane Library, and CNKI databases ...
Jie Gong, Fengwei Gao, Kangyi Jiang, Qingyun Xie, Xin Zhao, Zehua Lei   +5 more
doaj   +1 more source

A treat‐to‐target approach for obesity management: A post hoc analysis of the SURMOUNT‐5 trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Introduction With new advancements in obesity medicine, clarity on goals and expectations for successful disease management is limited. This post hoc analysis assessed application of proposed treat‐to‐target (TtT) thresholds for obesity to the outcome measures of SURMOUNT‐5, which randomised participants with obesity to tirzepatide or ...
Carel W. le Roux, Luca Busetto, Louis Aronne, Deborah Bade Horn, Georgios K. Dimitriadis, Beverly Falcon, Luis‐Emilio Garcia‐Perez, Elisa Gomez Valderas, Theresa Hunter Gibble, Cagri Senyucel, Julia P. Dunn   +10 more
wiley   +1 more source

Tirzepatide, a dual GIP/GLP-1 receptor agonist, alleviates metabolic dysfunction-associated steatotic liver disease by reducing the expression of CD36 and OBP2A

Genes and Diseases
Metabolic dysfunction-associated steatotic liver disease (MASLD) is defined by excessive hepatic lipid accumulation. This study evaluated the therapeutic effects and molecular mechanisms of tirzepatide, a dual GIP and GLP-1 receptor agonist, in treating ...
Yun Li, Wencong Sun, Hong Liu, Xiong Z. Ruan   +3 more
doaj   +1 more source

Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD), characterised by hepatic steatosis and metabolic dysfunction (i.e., obesity, type 2 diabetes, dyslipidaemia, and hypertension), is affecting over 30% of the adult population worldwide.
Lanlan Chen, Paul Horn, Frank Tacke
wiley   +1 more source

Case Report: Rhabdomyolysis following initiation of tirzepatide

Frontiers in Pharmacology
We present the case of a 66-year-old woman who developed weakness, nausea, and vomiting accompanied by markedly elevated creatine kinase levels after first treatment with an increased dose of tirzepatide.
Jonas Michael Bodanowitz, Isabell Mattes, Micha Loebermann, Carlos Fritzsche   +3 more
doaj   +1 more source

Real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi‐site retrospective study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Despite the established efficacy of tirzepatide in randomised controlled trials, real‐world effectiveness data in Japanese patients remain limited. This study evaluated the real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes over 52 weeks.
Yusuke Minakata, Masaki Miura, Nobuhiro Nakatake, Masahiro Masuzawa   +3 more
wiley   +1 more source